Ambrx Biopharma (Ambrx Biopharma) EPS (Basic) : $-1.33 (TTM As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Ambrx Biopharma EPS (Basic)?

Ambrx Biopharma's basic earnings per share (Basic EPS) for the three months ended in Jun. 2023 was $-0.63. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2023 was $-1.33.

Ambrx Biopharma's EPS (Diluted) for the three months ended in Jun. 2023 was $-0.63. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-1.33.

Ambrx Biopharma's EPS without NRI for the three months ended in Jun. 2023 was $-0.66. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2023 was -1.38.

During the past 3 years, the average EPS without NRI Growth Rate was 10.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 4 years, Ambrx Biopharma's highest 3-Year average EPS without NRI Growth Rate was 10.30% per year. The lowest was 10.30% per year. And the median was 10.30% per year.

Ambrx Biopharma EPS (Basic) Historical Data

The historical data trend for Ambrx Biopharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ambrx Biopharma EPS (Basic) Chart

Ambrx Biopharma Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

EPS (Basic)

-0.53

-0.44

-3.36

-2.03

Ambrx Biopharma Quarterly Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
EPS (Basic)	Get a 7-Day Free Trial			-11.41	-1.01	-1.33	-0.70	-0.63

Ambrx Biopharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Ambrx Biopharma's Basic EPS for the fiscal year that ended in Dec. 2022 is calculated as

Basic EPS (A: Dec. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-77.996	-	0)	/	38.606
	=	-2.02

Ambrx Biopharma's Basic EPS for the quarter that ended in Jun. 2023 is calculated as

Basic EPS (Q: Jun. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-33.128	-	0)	/	50.477
	=	-0.66

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.33

Ambrx Biopharma (NAS:AMAM) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Ambrx Biopharma EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Ambrx Biopharma's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Ambrx Biopharma (Ambrx Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ambrx Biopharma Inc (NAS:AMAM) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

AMAM:USA

Address

10975 North Torrey Pines Road, La Jolla, CA, USA, 92037

Website

https://www.ambrx.com

Ambrx Biopharma Inc is a clinical-stage biologics company focused on discovering and developing a novel class of engineered precision biologics (EPBs) using its proprietary expanded genetic code technology platform that allows incorporating synthetic amino acids (SAAs) into proteins within living cells. Its product pipeline includes ARX788, ARX517, ARX305 among others.

Executives

Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Margaret Dalesandro	director	ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Sonja Nelson	officer: Chief Financial Officer	C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BOULEVARD, 3RD FLOOR, FT. LAUDERDALE FL 33301
Daniel J. O'connor	director, officer: President and CEO	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Abhishek Trehan	10 percent owner	WHITELEY CHAMBERS, DON STREET, ST. HELIER Y9 JE2 4TR
Darwin Global Master Fund, Ltd.	10 percent owner	C/O OGIER GLOBAL (CAYMAN) LIMITED, 89 NEXUS WAY, CAMANA BAY, GRAND CAYMAN E9 KY1-9009
Paul V Maier	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Janet Loesberg	director	C/O AMBRX BIOPHARMA INC., 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Kate Hermans	director	C/O AMBRX BIOPHARMA INC., 10975 TORREY PINES ROAD, LA JOLLA CA 92037
Xiaowei Chang	director	10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Stephen C. Glover	director	108 DOCKSIDE CIRCLE, WESTON FL 33327
Andrew Aromando	officer: Chief Operating Officer	C/O AMBRX BIOPHARMA INC., 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Cormorant Private Healthcare Fund Iii Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen	10 percent owner	C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116